30 August 2022
Directa Plus plc
("Directa Plus" or the "Company")
Notice of Allowance for US Patent
Directa Plus (AIM: DCTA), a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets, announces that the Company has received a Notice of Allowance from the United States Patent and Trademark Office for the grant of a patent covering the Company's G+® embedded polyurethane membrane, developed explicitly for the textile industry, together with its production method and its applications. The patent, titled "Polyurethane film comprising graphene and preparation process thereof", has a priority date of 5 May 2017. The official grant, expected shortly, will follow on from the completion of the filing process.
G+® membranes are highly functional membranes that combine breathability and water protection with thermal and electrical conductivity. They provide superior thermal comfort by enhancing heat retention, due to high infrared absorption, while equalising it as a result of high in-plane thermal conductivity. They are electrically conductive, and the conductivity properties can be adjusted to confer antistatic behaviours for heating. Directa Plus' G+® membranes are non-toxic, non-cytotoxic, and safe against the skin. The membranes are used in apparel markets including the sportswear, workwear, military, luxury and accessories segments. In addition, they are being developed for use in the automotive, filtration and upholstery markets.
Following the official grant of the patent, Directa Plus's IP portfolio will comprise 20 patent families with 80 patents granted and 30 patents pending.
Commenting, Giulio Cesareo, Founder and CEO of Directa Plus, said: "Our core textile offering is generating considerable interest in the US market and therefore patent protection, and defence, in the territories in which we operate remains a fundamental part of our strategy to create value for shareholders."
For further information please visit http://www.directa-plus.com/ or contact:
Directa Plus plc | +39 02 36714458 |
Giulio Cesareo, CEO / Giorgio Bonfanti, CFO | |
| |
Cenkos Securities plc (Nominated Adviser and Joint Broker) | +44 131 220 6939 |
Neil McDonald / Adam Rae | |
| |
Singer Capital Markets (Joint Broker) | +44 20 7496 3069 |
Rick Thompson / Phil Davies | |
| |
Tavistock (Financial PR and IR) | +44 20 7920 3150 |
Simon Hudson / Heather Armstrong | |
About Directa Plus
Directa Plus (www.directa-plus.com) is one of the largest producers and suppliers of graphene-based products for use in consumer and industrial markets. The Company's graphene manufacturing capability uses proprietary patented technology based on a plasma super expansion process. Starting from natural graphite, each step of Directa Plus' production process - expansion, exfoliation and drying - creates graphene-based materials and hybrid graphene materials ready for a variety of uses and available in various forms such as powder, liquid and paste.
This proprietary production process uses a physical process, rather than a chemical process, to process graphite into pristine graphene nanoplatelets, which enables Directa Plus to offer a sustainable, non-toxic product, without unwanted by-products. Directa Plus' products are made of hybrid graphene materials and graphene nano-platelets. The products (marketed as G+®) have multiple applications due to its properties. These G+® products can be categorised into various families, with different products being suitable for specific practical applications.
Directa Plus was established in 2005 and is based in Lomazzo (Como, Italy) and has been listed on the AIM market of the London Stock Exchange since May 2016. The Company holds the Green Economy Mark from London Stock Exchange which recognises companies that contribute to the global green economy.
-ends-
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.